Janux Therapeutics (JANX) closed FY 2025 with Q4 revenue of US$0 million and a basic EPS loss of US$0.51, alongside a trailing twelve month basic EPS loss of US$1.83 on US$10 million of revenue, with a clear focus on how much growth is costing. Over the past six reported quarters, the company has seen quarterly revenue range from US$0 million to US$13.05 million while basic EPS has moved between losses of US$0.36 and US$0.55, giving investors a detailed view of how the top line and per share results are tracking through the development cycle. Taken together with expectations for strong revenue expansion but ongoing losses, this mix of modest revenue and sizeable EPS pressure keeps the spotlight firmly on margins and on how efficiently future growth can be converted into earnings.

See our full analysis for Janux Therapeutics.

With the latest figures on the table, the next step is to see how these results line up with the key narratives around Janux Therapeutics, highlighting where the growth story and the risk of prolonged losses either match or push back against current market views.

Losses widen to US$113.6 million over the year

• On a trailing twelve month basis to Q4 FY 2025, Janux reported US$10 million of revenue alongside a net loss of US$113.6 million and a basic EPS loss of US$1.83, compared with a trailing twelve month net loss of US$60.5 million and basic EPS loss of US$1.18 a year earlier.
• Bears point to this widening loss profile as backing the view that earnings are under pressure, with the last twelve months showing US$113.6 million of losses. Analysts also expect earnings to decline on average by 15.3% per year over the next three years, yet the same data highlights a forecast 53.48% annual revenue growth rate. This means the key question for this bearish view is how long investors will accept larger losses alongside that stronger top line outlook.
  • Critics highlight that the company has been unprofitable for the past five years and losses have grown at about 30.4% per year, which is consistent with the most recent trailing twelve month loss widening from US$68.9 million at Q4 FY 2024 to US$113.6 million at Q4 FY 2025.
  • What stands out against this bearish angle is that forecast revenue growth of 53.48% per year sits alongside these projected earnings declines. The numbers suggest a trade off between expansion in the business and the likelihood of further losses for now.

Quarterly swings show revenue lumpy, losses persistent

• Looking at individual quarters in FY 2025, revenue moved between US$0 and US$10 million while net loss ranged from US$23.5 million to US$33.9 million and basic EPS loss stayed in a narrow band of US$0.38 to US$0.55 per share. This underlines that quarterly volatility in revenue has not yet translated into any quarter close to breakeven.
• Bears argue that this pattern reinforces the idea of structurally loss making operations, since Q3 FY 2025 generated US$10 million of revenue yet still produced a US$24.3 million loss and US$0.39 EPS loss. Two other quarters in FY 2025 reported zero revenue but losses between US$23.5 million and US$33.9 million, so the current data set suggests revenue contributions, when they appear, have not yet meaningfully shifted the bottom line.
  • In Q2 FY 2025, for example, Janux recorded no revenue but still reported a US$33.9 million loss and US$0.55 EPS loss, which is similar in scale to the Q3 loss level that included US$10 million of revenue.
  • Over the last six reported quarters, net loss has ranged from US$20.2 million to US$33.9 million even as revenue has moved between US$0 and US$13.0 million. This supports the bearish concern that expense levels currently dominate the income statement regardless of short term revenue contributions.

Low 0.9x P/B contrasts with growth and earnings forecasts

• The stock trades on a P/B of 0.9x compared with about 2.5x for the US Biotech industry and around 4.6x for peers, while revenue is forecast to grow at 53.48% per year and earnings are expected to decline on average by 15.3% per year over the next three years, with the company remaining unprofitable over that horizon.
• Bullish investors often point to the combination of a low 0.9x P/B multiple and strong forecast revenue growth as support for upside potential. The same data also shows ongoing losses and expected earnings declines, so the bullish case needs to explain why paying below industry book value for a company with US$113.6 million of trailing twelve month losses and no clear path to profitability over the next three years could still appeal.
  • Supporters note that the discount to the industry P/B of 2.5x and peer average of 4.6x suggests the market price is not assigning the same value to Janux’s balance sheet as to other biotechs, even though the forecast revenue growth rate of 53.48% per year is described as strong within the data set.
  • At the same time, the forecast average 15.3% annual decline in earnings and the history of losses growing about 30.4% per year over five years mean the numbers currently mirror both sides of the bullish narrative, combining an apparently low entry multiple with financials that still show substantial and persistent losses.

For a clearer sense of how other investors are interpreting this mix of fast forecast revenue growth, deep current losses, and a discounted P/B multiple, it can help to see how different narratives frame the same set of numbers, which is where community views come in through the Curious how numbers become stories that shape markets? Explore Community Narratives.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Janux Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mix of pressure from losses and potential from growth, it makes sense to look at the data yourself and decide where you stand, then weigh both sides by checking the 1 key reward and 2 important warning signs.

Explore Alternatives

Janux Therapeutics currently combines deep and persistent losses with lumpy revenue and no clear route to profitability over the next several years.

If this level of ongoing loss makes you want steadier foundations, compare it with companies screened for stronger financial resilience through the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.